Wednesday, November 23, 2022

New Omicron subvariant BQ.1.1 resistant to all therapeutic antibodies, study finds

Are the currently approved antibody therapies used to treat individuals at increased risk for severe COVID-19 disease also effective against currently circulating viral variants? A recent study shows that the Omicron sub-lineage BQ.1.1, currently on the rise worldwide, is resistant to all approved antibody therapies.

from Latest Science News -- ScienceDaily https://ift.tt/rqkGHtK
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Study finds untreated sleep apnea doubles Parkinson’s risk

A massive veteran study found a strong connection between untreated sleep apnea and a higher chance of Parkinson’s. CPAP users had much lowe...